Evolva Holding SA (EVE.SW)

CHF 0.84

(-6.44%)

Net Income Summary of Evolva Holding SA

  • Evolva Holding SA's latest annual net income in 2023 was -105.22 Million CHF , down -133.4% from previous year.
  • Evolva Holding SA's latest quarterly net income in 2024 Q2 was 1.34 Million CHF , down 0.0% from previous quarter.
  • Evolva Holding SA reported an annual net income of -43.36 Million CHF in 2022, down -5.09% from previous year.
  • Evolva Holding SA reported an annual net income of -41.26 Million CHF in 2021, down -38.15% from previous year.
  • Evolva Holding SA reported a quarterly net income of -79.64 Million CHF for 2023 Q2, down 0.0% from previous quarter.
  • Evolva Holding SA reported a quarterly net income of -21.57 Million CHF for 2023 Q4, down 0.0% from previous quarter.

Annual Net Income Chart of Evolva Holding SA (2023 - 2005)

Historical Annual Net Income of Evolva Holding SA (2023 - 2005)

Year Net Income Net Income Growth
2023 -105.22 Million CHF -133.4%
2022 -43.36 Million CHF -5.09%
2021 -41.26 Million CHF -38.15%
2020 -29.87 Million CHF -38.04%
2019 -21.63 Million CHF 25.93%
2018 -29.21 Million CHF 25.05%
2017 -38.97 Million CHF -8.36%
2016 -35.97 Million CHF -12.79%
2015 -31.89 Million CHF -49.36%
2014 -21.35 Million CHF -35.73%
2013 -15.73 Million CHF 2.23%
2012 -16.08 Million CHF 28.34%
2011 -22.45 Million CHF 3.63%
2010 -23.29 Million CHF -142.47%
2009 -9.6 Million CHF 85.54%
2008 -66.45 Million CHF -12.4%
2007 -59.12 Million CHF 18.49%
2006 -72.53 Million CHF -106.98%
2005 -35.04 Million CHF 0.0%

Peer Net Income Comparison of Evolva Holding SA

Name Net Income Net Income Difference
Addex Therapeutics Ltd -10.55 Million CHF -896.847%
BB Biotech AG -206.6 Million CHF 49.068%
Basilea Pharmaceutica AG 10.45 Million CHF 1106.884%
Idorsia Ltd -297.92 Million CHF 64.679%
Kuros Biosciences AG -13.72 Million CHF -666.587%
Molecular Partners AG -61.98 Million CHF -69.769%
Relief Therapeutics Holding AG -98.18 Million CHF -7.179%
Santhera Pharmaceuticals Holding AG 54.78 Million CHF 292.088%